0000899243-22-034545.txt : 20221031 0000899243-22-034545.hdr.sgml : 20221031 20221031160515 ACCESSION NUMBER: 0000899243-22-034545 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20221021 FILED AS OF DATE: 20221031 DATE AS OF CHANGE: 20221031 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Astellas Pharma Inc. CENTRAL INDEX KEY: 0001376684 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 221345990 BUSINESS ADDRESS: STREET 1: 2-5-1, NIHONBASHI-HONCHO STREET 2: CHUO-KU CITY: TOKYO STATE: M0 ZIP: 103-8411 BUSINESS PHONE: 81-3-3244-3231 MAIL ADDRESS: STREET 1: 2-5-1, NIHONBASHI-HONCHO STREET 2: CHUO-KU CITY: TOKYO STATE: M0 ZIP: 103-8411 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Audentes Therapeutics, Inc. CENTRAL INDEX KEY: 0001628738 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 221345991 BUSINESS ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 BUSINESS PHONE: 415-638-6556 MAIL ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-10-21 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001628738 Audentes Therapeutics, Inc. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO CA 94108 0 0 1 0 0001376684 Astellas Pharma Inc. 2-5-1, NIHONBASHI-HONCHO, CHUO-KU TOKYO M0 103-8411 JAPAN 0 0 1 0 Common Stock 7266342 D The securities are directly held by Audentes Therapeutics, Inc., a Delaware corporation, ("Audentes") a wholly owned direct subsidiary of Astellas US Holding, Inc., a Delaware corporation, ("Astellas US") which is in turn a wholly owned direct subsidiary of Astellas Pharma Inc., a corporation established under the laws of Japan ("Astellas"). Under SEC rules and regulations, each of Astellas and Astellas US may be deemed to have indirect beneficial ownership of the shares held by Audentes, which has direct beneficial ownership. Exhibit List Exhibit 24.1 - Power of Attorney (Astellas) Exhibit 24.2 - Power of Attorney (Audentes) /s/ Chad Diehl, Attorney-in-Fact, Astellas 2022-10-31 /s/ Chad Diehl, Attorney-in-Fact, Audentes 2022-10-31 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT 
                                POWER OF ATTORNEY

Know all by these presents, that Astellas Pharma Inc. (the "Company") hereby
constitutes and appoints each of Chad Diehl and Lujing Liu, or either of them
signing singly, and with full power of substitution, the Company's true and
lawful attorney-in-fact to:

(1) prepare, execute in the Company's name and on the Company's behalf, and
submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain codes and passwords enabling the Company to make electronic filings
with the SEC of reports required by Sections 13 or 16(a) of the Securities
Exchange Act of 1934 (the "Exchange Act") or any rule or regulation of the SEC;

(2) prepare, execute in the Company's name and on the Company's behalf, and
submit to the SEC (i) beneficial ownership reports on Schedule 13D or 13G, in
accordance with Section 13 of the Exchange Act and the rules thereunder, (ii)
Forms 3, 4, and 5, in accordance with Section 16(a) of the Exchange Act and the
rules thereunder and (iii) Forms 144, in accordance with the Securities Act of
1933 (the "Securities Act") and the rules thereunder (collectively, the
"Covered Forms");

(3) do and perform any and all acts for and on behalf of the Company which may
be necessary or desirable to complete and execute any Covered Form, complete
and execute any amendment or amendments thereto, and timely file such form with
the SEC and any stock exchange or similar authority; and

(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the Company, it being
understood that the documents executed by such attorney-in-fact on behalf of
the Company pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in- fact's discretion.

The Company hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, with full power of substitution or revocation, hereby ratifying
and confirming all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this power of attorney and the rights and powers herein granted. The Company
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the Company, are not assuming any of the Company's
responsibilities to comply with Sections 13 or 16 of the Exchange Act or the
provisions of the Securities Act. This Power of Attorney shall remain in full
force and effect for a period of five (5) years from the date hereof, unless
earlier revoked by the Company in a signed writing delivered to the foregoing
attorneys-in-fact.

                             [Signature Page Follows]

IN WITNESS WHEREOF, the Company has caused this Power of Attorney to be
executed as of this 28th day of October, 2022.


                                   ASTELLAS PHARMA INC.

                                   By:   /s/ Naoki Okamura
                                         ----------------------------------
                                   Name:     Naoki Okamura
                                   Title: Representative Director, Executive
                                          Vice President
EX-24.2 3 attachment2.htm EX-24.2 DOCUMENT 
                                POWER OF ATTORNEY

Know all by these presents, that Audentes Therapeutics, Inc. (the "Company")
hereby constitutes and appoints each of Chad Diehl and Lujing Liu, or either of
them signing singly, and with full power of substitution, the Company's true
and lawful attorney-in-fact to:

(1) prepare, execute in the Company's name and on the Company's behalf, and
submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain codes and passwords enabling the Company to make electronic filings
with the SEC of reports required by Sections 13 or 16(a) of the Securities
Exchange Act of 1934 (the "Exchange Act") or any rule or regulation of the SEC;

(2) prepare, execute in the Company's name and on the Company's behalf, and
submit to the SEC (i) beneficial ownership reports on Schedule 13D or 13G, in
accordance with Section 13 of the Exchange Act and the rules thereunder, (ii)
Forms 3, 4, and 5, in accordance with Section 16(a) of the Exchange Act and the
rules thereunder and (iii) Forms 144, in accordance with the Securities Act of
1933 (the "Securities Act") and the rules thereunder (collectively, the
"Covered Forms");

(3) do and perform any and all acts for and on behalf of the Company which may
be necessary or desirable to complete and execute any Covered Form, complete
and execute any amendment or amendments thereto, and timely file such form with
the SEC and any stock exchange or similar authority; and

(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the Company, it being
understood that the documents executed by such attorney-in-fact on behalf of
the Company pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in- fact's discretion.

The Company hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, with full power of substitution or revocation, hereby ratifying
and confirming all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this power of attorney and the rights and powers herein granted. The Company
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the Company, are not assuming any of the Company's
responsibilities to comply with Sections 13 or 16 of the Exchange Act or the
provisions of the Securities Act. This Power of Attorney shall remain in full
force and effect for a period of five (5) years from the date hereof, unless
earlier revoked by the Company in a signed writing delivered to the foregoing
attorneys-in-fact.

                             [Signature Page Follows]

IN WITNESS WHEREOF, the Company has caused this Power of Attorney to be
executed as of this 26th day of October, 2022.

                                   AUDENTES THERAPEUTICS, INC.

                                   By:    /s/ Nahrin S. Marino
                                          -------------------------------
                                   Name:  Nahrin S. Marino
                                   Title: SVP, Legal
                                          Secretary